Nahoko Baileykobayashi

This inventor holds 30 USPTO granted patents and 12 published patent applications and 5 EPO patents, primarily in Antitumor Peptides. Top assignees: Toagosei Company, Ltd., Nagoya University, Kyoto University. Active years: 2018-2025.

USPTO Granted Patents = 30 (Patent Applications = 12)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 20)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 121(Granted Patents)

Location History:

Ibaraki, JP (2018 - 2022)
Ibaraki-ken, JP (2022)
Tokyo, JP (2022)
Tsukuba-Ibaraki-ken, JP (2022)
Tsukuba, JP (2018 - 2024)

Company Filing History:

28 out of 273

Toagosei Company, Ltd.

National University Corporation Nagoya

patents

7. 1 out of 1,352

The University of Tokyo

patents

8. 1 out of 57

University Public Corporation Osaka

patents

9. 2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 2018-2025

Loading Chart...

Areas of Expertise:

Antitumor Peptide

Antiviral Peptide

SARS-CoV-2

Peptide Suppression

Diagnostic Methods

Synthetic Peptide

Myocardial Cells

Stem Cells

Cell Differentiation

CD47 Inhibition

Exosome Production

Nucleolar Localization

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12392770 - Foreign substance introduction construct and use thereof (2025-08-19),

2. 12285476 - Amino acid sequence derived from S protein of SARS-CoV2 for generating an anti-SARS-CoV-2 antibody (2025-04-29),

3. 12209242 - siRNA based on RNA sequence of SARS-CoV-2 and use thereof (2025-01-28),

4. 11965011 - Antitumor peptide and use thereof (2024-04-23),

5. 11927589 - Carrier peptide fragment for nucleolar localization and use thereof (2024-03-12),

6. 11814448 - Carrier peptide fragment and use thereof (2023-11-14),

7. 11780903 - Peptide suppressing binding of CTLA4 to B7 proteins, and use thereof (2023-10-10),

8. 11767345 - Antiviral peptide and use thereof (2023-09-26),

9. 11603395 - Antitumor peptide and use thereof (2023-03-14),

10. 11505589 - Antitumor peptide and use thereof (2022-11-22),

11. 11472845 - Antitumor peptide and use thereof (2022-10-18),

12. 11359180 - Method for producing myocardial cells using synthetic peptide (2022-06-14),

13. 11352408 - Antitumor peptide having PD-1 signal sequence and utilization thereof (2022-06-07),

14. 11339203 - Antitumor peptide and use thereof (2022-05-24),

15. 11324831 - Method for introducing exogenous substance into cell, and material used in said method (2022-05-10),

Title: Innovations and Contributions of Nahoko Baileykobayashi

Introduction

Nahoko Baileykobayashi, an inventive mind located in Tsukuba, Japan, has made significant contributions to the field of biotechnology. With a remarkable portfolio of 28 patents, Baileykobayashi's work primarily focuses on innovative therapeutic approaches targeting viral infections and cancer.

Latest Patents

Among his latest patents, Baileykobayashi developed an siRNA based on the RNA sequence of SARS-CoV-2. This invention presents a novel approach to suppressing the proliferation of new coronaviruses. The siRNA consists of a sense strand that incorporates a target sequence comprising 19 to 23 bases with specific terminal requirements and an antisense strand that is complementary to the sense strand. Specifically, the target sequence includes segments that encode a signal peptide region of the spike protein of SARS-CoV-2. In addition, his patent on an antitumor peptide highlights his dedication to addressing cancer, showcasing innovative methodologies in therapeutic peptide design.

Career Highlights

Throughout his career, Baileykobayashi has been associated with esteemed organizations, including Toagosei Company, Ltd. and the National University Corporation Nagoya University. His work in these institutions has fostered a collaborative environment to advance research and innovation.

Collaborations

Collaboration is a key aspect of Baileykobayashi's career. He has worked closely with notable researchers such as Tetsuhiko Yoshida and Makoto Sawada, contributing to a wealth of knowledge in the field. These partnerships have been instrumental in driving forward innovative solutions to contemporary health challenges.

Conclusion

Nahoko Baileykobayashi's contributions to biotechnology, particularly in the development of siRNA therapies and antitumor peptides, underscore his role as a leading inventor in the sector. With a strong foundation in both academia and industry, his work continues to inspire advancements in medical science.